



**Millendo Therapeutics, Inc. to Present  
at the Cowen and Company 39<sup>th</sup> Annual Healthcare Conference and  
the Oppenheimer 29<sup>th</sup> Annual Healthcare Conference**

**ANN ARBOR, Mich., March 4, 2019** – [Millendo Therapeutics, Inc.](http://investors.millendo.com) (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences.

**Details on the Presentations:**

**Event:** Cowen & Company 39<sup>th</sup> Annual Health Care Conference

**Date/Time:** Monday, March 11, 2019 at 1:30 p.m. ET

**Location:** Boston, MA

**Event:** Oppenheimer 29<sup>th</sup> Annual Healthcare Conference

**Date/Time:** Tuesday, March 19, 2019 at 3:55 p.m. ET

**Location:** New York, NY

Live webcasts of both presentations will be available on the Investors & Media section of Millendo's website at <http://investors.millendo.com>. Replays of the webcasts will be archived on Millendo's website for 30 days following the presentation.

**About Millendo Therapeutics, Inc.**

Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The Company's objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing's syndrome. For more information, please visit [www.millendo.com](http://www.millendo.com).

**Millendo Investor Contact:**

Stephanie Ascher

Stern Investor Relations

212-362-1200

[stephanie@sternir.com](mailto:stephanie@sternir.com)

**Millendo Media Contact:**

Betsy Yates

MacDougall

781-235-3094

[byates@macbiocom.com](mailto:byates@macbiocom.com)

##